Oxford BioDynamics Plc
OXBOF · OTC
9/30/2024 | 9/30/2023 | 9/30/2022 | 9/30/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | -0.17 | 0.02 | -0.21 |
| FCF Yield | -97.10% | -53.24% | -680.80% | -11.52% |
| EV / EBITDA | -1.46 | -1.84 | -0.89 | -12.85 |
| Quality | ||||
| ROIC | -117.78% | -74.53% | -83.18% | -47.96% |
| Gross Margin | 45.44% | 52.16% | 75.32% | -163.34% |
| Cash Conversion Ratio | 0.85 | 0.73 | 0.68 | 0.78 |
| Growth | ||||
| Revenue 3-Year CAGR | 60.44% | 14.36% | -30.36% | -27.83% |
| Free Cash Flow Growth | -19.50% | -48.24% | 32.52% | -133.46% |
| Safety | ||||
| Net Debt / EBITDA | -0.38 | -0.12 | -0.76 | -0.69 |
| Interest Coverage | -57.31 | -47.74 | -44.11 | -65.89 |
| Efficiency | ||||
| Inventory Turnover | 1.08 | 0.89 | 0.11 | 2.29 |
| Cash Conversion Cycle | 130.07 | -261.24 | -4,966.30 | 391.54 |